Lidds AB
LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemoth… Read more
Lidds AB (LIDDS) - Total Liabilities
Latest total liabilities as of September 2025: Skr491.00K SEK
Based on the latest financial reports, Lidds AB (LIDDS) has total liabilities worth Skr491.00K SEK as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Lidds AB - Total Liabilities Trend (2010–2024)
This chart illustrates how Lidds AB's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Lidds AB Competitors by Total Liabilities
The table below lists competitors of Lidds AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
KOPPERS HLDGS
BE:KO9
|
Germany | €1.43 Billion |
|
Generation Income Properties Inc Warrant
NASDAQ:GIPRW
|
USA | $74.52 Million |
|
SKANSKA -B- - Dusseldorf Stock Exchang
DU:SKNB
|
Germany | €103.85 Billion |
|
Sprott Physical Silver
TO:PSLV
|
Canada | CA$66.84 Million |
|
Latitude Tree Holdings Bhd
KLSE:7006
|
Malaysia | RM140.25 Million |
|
WaterBridge Infrastructure LLC
NYSE:WBI
|
USA | $2.08 Billion |
Liability Composition Analysis (2010–2024)
This chart breaks down Lidds AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.04 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 3.53 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lidds AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lidds AB (2010–2024)
The table below shows the annual total liabilities of Lidds AB from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr1.98 Million | -47.31% |
| 2023-12-31 | Skr3.76 Million | -64.47% |
| 2022-12-31 | Skr10.57 Million | +49.58% |
| 2021-12-31 | Skr7.07 Million | -37.99% |
| 2020-12-31 | Skr11.40 Million | +91.05% |
| 2019-12-31 | Skr5.96 Million | +22.76% |
| 2018-12-31 | Skr4.86 Million | +36.48% |
| 2017-12-31 | Skr3.56 Million | -58.06% |
| 2016-12-31 | Skr8.49 Million | +229.98% |
| 2015-12-31 | Skr2.57 Million | +10.96% |
| 2014-12-31 | Skr2.32 Million | +47.07% |
| 2013-12-31 | Skr1.58 Million | -55.24% |
| 2012-12-31 | Skr3.52 Million | +107.08% |
| 2011-12-31 | Skr1.70 Million | +42.38% |
| 2010-12-31 | Skr1.19 Million | -- |